Antibody Glycoengineering for Enhanced Therapeutic Efficacy

Please register via: https://us06web.zoom.us/webinar/register/WN_tvOjv2qUTreMCoObuJejdw?sessionid=1094962281#/registration

Abstract: Glycosylation is a critical determinant of antibody’s functions and overall therapeutic efficacy. The conserved Fc N-glycan of IgG antibodies, for instance, plays a pivotal role in modulating interactions with Fcγ receptors and downstream activities such as antibody-dependent cellular cytotoxicity. However, achieving precise control over antibody glycosylation with optimal therapeutic performance remains a significant challenge. On the other hand, antibody–drug conjugates (ADCs), which harness the specificity of antibodies to deliver highly cytotoxic agents for targeted cell killing, have emerged as a promising strategy for cancer therapy. In this webinar, we will present a chemoenzymatic glycoengineering platform that enables the synthesis of homogeneous antibody glycoforms with enhanced anticancer and anti-inflammatory activities. Furthermore, extension of this approach to bioconjugation allows production of site-specific antibody–drug and antibody–ligand conjugates, facilitating precise targeted cell killing and protein degradation. Taken together, these chemoenzymatic glycoengineering strategies provide powerful tools for producing structurally well-defined antibody glycoforms and site-specific ADCs, with significant potential to advance the development of next-generation antibody-based therapeutics.

Speaker: Dr. Lai-Xi Wang is a Distinguished University Professor of Chemistry and Biochemistry at the University of Maryland, College Park, and the Founder and president of GlycoT Therapeutics. He received his Ph.D. from the Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences. Following postdoctoral studies at Johns Hopkins University and the Massachusetts Institute of Technology (MIT), he joined the Institute of Human Virology at the University of Maryland School of Medicine as a tenure-track assistant professor in 2000. He was promoted to associate professor in 2005 and full professor in 2009. In 2015, he was recruited to the University of Maryland, College Park, to lead the chemical biology program. Dr. Wang’s research spans bioorganic chemistry, carbohydrate chemistry, enzymology, glycobiology, and immunology. His recent work focuses on the development of innovative chemical and enzymatic approaches for antibody glycoengineering and site-specific antibody–drug conjugates. He has published more than 220 peer-reviewed articles and is the lead inventor on 36 U.S. and international patents. Dr. Wang has received numerous honors recognizing his research, teaching, and entrepreneurship, including the Melville L. Wolfrom Award (2014) from the American Chemical Society, as well as the Dean’s Award for Excellence in Teaching (2020) and the Norma M. Allewell Prize in Entrepreneurship (2021) from the University of Maryland. He is an elected Fellow of AAAS (2014), the American Chemical Society (ACS, 2019), and the National Academy of Inventors (2023). 

Sponsor: Sino Biological

Sino Biological is a leading global reagent supplier and contract research service provider with 19 years of experience in protein production and antibody development. We offer a vast catalogue of 10,000+ recombinant proteins and 15,000+ antibodies. Our proprietary technology platforms enable customized, end-to-end solutions for customers with complex protein and antibody needs.

By streamlining high-throughput antibody production and developability assessment, Sino Biological’s integrated platform accelerates high-quality data generation, empowering AI antibody discovery and model training. Powered by dual expression systems—mammalian cells (10,000+ antibodies/month) and cell-free system (3-hour rapid expression)—the platform rapidly synthesizes thousands of AI-designed variants across a wide range of formats, including IgGs, scFvs, VHHs, Fabs, bispecifics, and mini-binders. Our comprehensive developability analysis integrates 20+ assays (AC-SINS, LC-MS, nanoDSF, HIC, BLI, BVP/DNA/Insulin ELISA, etc.) to evaluate key attributes like homogeneity, stability, solubility, and specificity, delivering AI-ready data efficiently.

Sino Biological is headquartered in Beijing, China, and has established subsidiaries in the US, Canada, Europe, Japan, and South Korea. Our global client base includes top pharmaceutical, biotech, and diagnostics companies, along with prestigious universities and research institutions in 90+ countries. Sino Biological is committed to advancing biotherapeutic development and forging a brighter future in the life sciences.